LLY · Eli Lilly and Company
AI read · Neutral
The AI's read
LLY fell with the weak healthcare sector, but its longer-term averages and analyst Buy consensus counter recent momentum weakness, leaving the story balanced for the company.
Eli Lilly's stock dropped on Tuesday. What's going on?
Neutral
Shares dropped about 2% tied to broad healthcare weakness, while longer-term moving averages and analyst Buy ratings counter recent momentum weakness.
NVS · Novartis AG
AI read · Bad for NVS
The connection
Novartis shares plunged after a Phase 3 HARBOR trial for del-desiran failed to meet its primary endpoint, pressuring the company.
IONS · Ionis Pharmaceuticals Inc.
AI read · Bad for IONS
The connection
The article links Ionis to the failed drug program and says the news weighed on the company because of financial ties to pelacarsen.
RPRX · Royalty Pharma plc
AI read · Bad for RPRX
The connection
Royalty Pharma is named as exposed to pelacarsen, and the failed trials are said to have weighed on its shares.
PINK · Simplify Health Care ETF
AI read · Neutral
The connection
The ETF holds a large weighting in Lilly so flows can affect it, but no ETF-specific news was reported in the story.
PCLG · Polen Focus Growth ETF
AI read · Neutral
The connection
The Polen Focus Growth ETF has meaningful Lilly exposure, but the article reports no direct news on the ETF itself.
Get alerts for LLY
Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LLYFree on the App Store and Google Play, or on the web.